Dear Editor,The molecular pathogenesis of estrogen receptor(ER)-negative,especially triple-negative breast cancer(TNBC),is unclear,thus,the treatment of these types of cancers is still a great challenge[1].Chemotherap...Dear Editor,The molecular pathogenesis of estrogen receptor(ER)-negative,especially triple-negative breast cancer(TNBC),is unclear,thus,the treatment of these types of cancers is still a great challenge[1].Chemotherapy remains the primary adjuvant treatment choice for TNBC patients[2],but a large number of these tumors are resistant to chemotherapy and relapse ormetastasize quickly after adjuvant therapy[3].展开更多
基金supported in part by NIH-NIMHD U54MD007598,U54CA143931,NIH/NCI1U54CA14393,U56 CA101599-01Department-of-Defense Breast Cancer Research Program grant BC043180,NIH/NCATS CTSI UL1TR000124 to J.V.Vadgama+1 种基金Accelerating Excellence in Translational Science(AXIS)Pilot Grants G0812D05,NIH/NCI SC1CA200517 and 9 SC1 GM135050-05 to Y.WuNIH/NIMHD Accelerating Excellence in Translational Science(AXIS)Pilot Grants G0814C01(Q.Hao).
文摘Dear Editor,The molecular pathogenesis of estrogen receptor(ER)-negative,especially triple-negative breast cancer(TNBC),is unclear,thus,the treatment of these types of cancers is still a great challenge[1].Chemotherapy remains the primary adjuvant treatment choice for TNBC patients[2],but a large number of these tumors are resistant to chemotherapy and relapse ormetastasize quickly after adjuvant therapy[3].
